Search results
Found 30406 matches for
Leeson Group: Preventive Cardiology Research Group
Cardiovascular Clinical Research Facility Division of Cardiovascular Medicine
Our aim is to develop better ways to identify early disease and improve cardiovascular health for young people. This is achieved by undertaking work in three areas: (1) Identification of novel markers of early disease to better understand how disease becomes established (2) Performing cardiovascular prevention trials in young adults to understand how to modify early disease and improve health (3) Application of artificial intelligence to imaging and research datasets to identify next generation imaging and management approaches.
Banning Group
Division of Cardiovascular Medicine
Use of minimally invasive techniques to improve heart function.
Bhattacharya Group: Developing novel therapeutics for inflammatory diseases
Division of Cardiovascular Medicine
Our goals are to develop therapeutics targeting the chemokine network in inflammatory diseases affecting the heart, blood vessels and other organ systems.
Lygate Group: Cardiac Energetics and Integrative Physiology
Division of Cardiovascular Medicine
We study how the heart meets its high and variable energy demands in order to identify novel strategies that may be beneficial in disease.
Carnicer Group
Division of Cardiovascular Medicine
Nitric oxide regulation of cardiac function, metabolism and inflammation in diabetes.
Gehmlich group: Biomechanical stress signalling in the heart and its role in cardiomyopathies
Division of Cardiovascular Medicine
We research genetic diseases of the heart (cardiomyopathies) that can lead to sudden cardiac death. An example of an individual with cardiomyopathy is the professional football player Fabrice Muamba, who collapsed on the pitch and had to be resuscitated. He was fortunate to survive his cardiac arrest and his case was featured in the media.
Choudhury Group: Understanding Inflammatory processes in Atherosclerosis and Acute Myocardial Infarction
Acute Multidisciplinary Imaging and Interventional Centre Division of Cardiovascular Medicine
This translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.
Douglas Group: Functional coronary artery disease genetics
Division of Cardiovascular Medicine
Defining the function of new causal atherosclerosis genes from CAD GWAS loci using in vitro and in vivo models.
Casadei Group: Translational approaches in chronic cardiac disease
Division of Cardiovascular Medicine
Our programme of work aims to understand nitric oxide (NO) and redox signalling in healthy and diseased myocardium, with a particular focus on atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Building on the resources and original discoveries that we have made recently, we plan to test novel interventions that aim to correct the myocardial substrate that promotes the new onset of AF, or HFpEF, or prevent the adverse atrial remodelling that is induced by AF.
Myerson Group: Heart Valve Disease
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
We investigate diseases of the heart valves – how widespread the problem is, what the causes are, who is at risk from future problems and what treatments can improve outcomes for patients.
Rider Group: Obesity, Heart Failure, Linking Myocardial Metabolism and Function
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
We use multi-parametric cardiac magnetic resonance imaging and multinuclear magnetic resonance spectroscopy to non-invasively investigate the relationship between cardiac metabolism and cardiac function.
Reilly Group: Molecular signalling in adverse myocardial remodelling and fibrosis
Division of Cardiovascular Medicine
Our group aims to understand the microRNA-mediated mechanisms fundamental to cardiac fibrosis and electrical remodelling that are associated with atrial fibrillation (a very common rhythm disorder). We are particularly interested in functional cross-talk between two major cell types in the heart – myocytes and fibroblasts.
Tzima Group: Mechanotransduction Group
Division of Cardiovascular Medicine
Vascular Mechanotransduction in health and disease.
Ramracheya Group: Pancreatic Islet and Gut Hormones in Health, Diabetes and Metabolic Surgery
Oxford Centre for Diabetes, Endocrinology and Metabolism
Our goal is to dissect the molecular mechanisms by which gut hormones, namely GLP-1 and PYY, improve glucose-mediated insulin and glucagon secretion in pancreatic islets. Dysfunction of both secretory processes contributes to the onset of type 2 diabetes and represents the target of effective diabetes intervention.
Rorsman Group
Oxford Centre for Diabetes, Endocrinology and Metabolism
We study cellular physiology of pancreatic islets – the small organs that regulate the whole-body sugar levels. Our work will help to find new treatments for diabetes – a disease that is characterised by uncontrolled blood sugar.
Thakker Group: Academic Endocrine Unit
Oxford Centre for Diabetes, Endocrinology and Metabolism
We investigate the genetic, molecular and physiological basis of endocrine disorders that affect calcium homeostasis, and endocrine tumour development. By identifying and understanding the underlying mechanisms, we aim to establish better diagnostic methods and develop novel targeted therapies for these disorders to improve patient care.
Karpe, Hodson and Christodoulides Group: Metabolic Research Group
Oxford Centre for Diabetes, Endocrinology and Metabolism
We apply an integrated approach to human metabolic disease which involves genetic, genomic, cell biology and whole body metabolic studies to understand the pathogenesis of the complications of obesity such as fatty liver disease, type 2 diabetes and cardiovascular disease.
Tomlinson Group: Metabolism and Steroid Hormone Biology
Oxford Centre for Diabetes, Endocrinology and Metabolism
We work to understand how hormones regulate metabolic health in liver, fat and skeletal muscle. Our research has helped to define the role of ‘pre-receptor’ hormone metabolism in the pathogenesis of metabolic disease and has contributed to the development of novel interventions with the ultimate aim of improving patient care.
Buchan Group: Responsible Research and Innovation
Investigative Medicine Division
We are focusing on how to make research and innovation relevant to society, sustainable and fair for everyone.
Rehwinkel Group: Nucleic Acid Sensing
Investigative Medicine Division MRC Translational Immune Discovery Unit MRC Weatherall Institute of Molecular Medicine